Technical Analysis for SBPH - Spring Bank Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 9.59 -6.35% -0.65
SBPH closed down 6.35 percent on Friday, March 22, 2019, on 2.03 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SBPH trend table...

Date Alert Name Type % Chg
Mar 22 MACD Bearish Centerline Cross Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 22 BB Squeeze Ended Range Expansion 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 21 Fell Below 20 DMA Bearish -6.35%
Mar 21 Fell Below 50 DMA Bearish -6.35%
Mar 21 Bollinger Band Squeeze Range Contraction -6.35%

Older signals for SBPH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that are design to target and modulate the activity of specific proteins implicated in various disease states. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops preclinical product candidates, such as SB 9400, SB 9941 and SB 9946 for RNA viral diseases. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Milford, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Disease Specialty Drugs Chronic Hepatitis B Virus Human Orthopneumovirus Preclinical Preclinical Product
Is SBPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.73
52 Week Low 8.14
Average Volume 17,725
200-Day Moving Average 11.6329
50-Day Moving Average 10.4988
20-Day Moving Average 10.302
10-Day Moving Average 10.435
Average True Range 0.5689
ADX 11.3
+DI 14.918
-DI 24.4834
Chandelier Exit (Long, 3 ATRs ) 9.2633
Chandelier Exit (Short, 3 ATRs ) 10.906699999999999
Upper Bollinger Band 10.9025
Lower Bollinger Band 9.7015
Percent B (%b) -0.09
BandWidth 11.65793
MACD Line -0.0321
MACD Signal Line -0.0048
MACD Histogram -0.0272
Fundamentals Value
Market Cap 121.77 Million
Num Shares 12.7 Million
EPS -2.50
Price-to-Earnings (P/E) Ratio -3.84
Price-to-Sales 0.00
Price-to-Book 4.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.12
Resistance 3 (R3) 11.16 10.69 10.87
Resistance 2 (R2) 10.69 10.30 10.67 10.78
Resistance 1 (R1) 10.14 10.06 9.91 10.10 10.69
Pivot Point 9.67 9.67 9.55 9.65 9.67
Support 1 (S1) 9.12 9.28 8.89 9.08 8.49
Support 2 (S2) 8.65 9.04 8.63 8.40
Support 3 (S3) 8.10 8.65 8.32
Support 4 (S4) 8.06